![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Amylin Pharmaceuticals, Inc. |
---|---|
Information provided by: | Amylin Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00044707 |
This is a randomized, single-blind, placebo-controlled, crossover study to examine the effect of pramlintide on the pharmacokinetics of an orally administered medication
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: Pramlintide acetate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Study ID Numbers: | 137-154 |
Study First Received: | September 3, 2002 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00044707 |
Health Authority: | United States: Food and Drug Administration |
Diabetes Mellitus, Type 2 |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Pramlintide Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |
Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |